Industry
Biotechnology
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Loading...
Open
4.58
Mkt cap
44M
Volume
3.5K
High
5.03
P/E Ratio
-9.84
52-wk high
5.82
Low
4.58
Div yield
N/A
52-wk low
3.34
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
February 27, 2024 | 10:24 pm
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 10:01 am
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 9:09 pm
Portfolio Pulse from saritha@benzinga.com
November 13, 2023 | 9:45 pm
Portfolio Pulse from Benzinga Insights
November 13, 2023 | 11:40 am
Portfolio Pulse from Happy Mohamed
October 05, 2023 | 8:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 29, 2023 | 12:10 pm
Portfolio Pulse from bharat@benzinga.com
August 10, 2023 | 8:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.